PARP1 and diabetes mellitus: In diabetes, however, PARP inhibitors may be therapeutically beneficial as inhibiting ADP-ribosylation suppresses inflammation and concurrently enhances PARP1 transcription activator function at the Reg promoter for β-cell regeneration [29].